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Introduction
The diagnosis of slowly progressive degenerative disorders in teenagers and adults remains challenging. Kufs disease, the paradigmatic form of late-onset neuronal ceroid lipofuscinoses, is one important cause; however, the clinicopathological literature is confusing and accurate diagnosis is difficult. In an earlier detailed review of cases reported as Kufs disease (Berkovic et al., 1988) , we found the diagnosis could be supported in only 50/118 cases and defined two types on the basis of the prominent clinical features: type A presenting as a progressive myoclonus epilepsy; and type B presenting as dementia with motor disturbance. Kufs disease differs from the more common childhood neuronal ceroid lipofuscinosis (NCL) forms, not only by its late onset, but also by the absence of retinal involvement. Contemporary challenges in diagnosis remain, as a recent analysis of 47 cases of putative Kufs disease showed that approximately a third had alternate diagnoses and, for many others, no diagnosis could be definitively substantiated (Berkovic et al., 2016) . The diagnosis traditionally has rested on characteristic pathology, which is most clearly shown in brain tissue, but is now rarely available.
With recent discoveries of the molecular genetic basis of many cases and families with Kufs disease, the diagnostic landscape is changing. Well established genes for recessive Kufs disease are CLN6 (Arsov et al., 2011; Andrade et al., 2012; Ozkara et al., 2017) and CTSF (Smith et al., 2013; Di Fabio et al., 2014; Bras et al., 2016; van der Zee et al., 2016) and for some dominant families, DNAJC5 (Benitez et al., 2011; Noskova et al., 2011; Velinov et al., 2012; Cadieux-Dion et al., 2013; Moro et al., 2014; Jarrett et al., 2018) . Recessive pathogenic variants of the progranulin gene (GRN) causes an adult form of NCL with visual impairment (Smith et al., 2012; Canafoglia et al., 2014; Almeida et al., 2016) , while heterozygous GRN variants are an important cause of fronto-temporal dementia. Additionally, there are other NCL genes where the presentation is normally in childhood, however, protracted or late onset forms have also been described that might present to the adult neurologist (Kousi et al., 2012; http://www.ucl.ac. uk/ncl/mutation.shtml) .
CLN6 pathogenic variants are the most common identified cause of recessive Kufs disease and, remarkably, also cause a late-infantile form of NCL. We initially reported seven CLN6 Kufs families (Arsov et al., 2011) and a handful of others have subsequently been reported (https://www. ucl.ac.uk/ncl/mutation.shtml, last updated 26/02/2018).
Here we present an analysis of 13 personally evaluated families with emphasis on the natural history, ultrastructural features in available pathology material and molecular genetics allowing a more complete description of CLN6-related Kufs disease. We compare the CLN6 molecular findings in those with teenage or adult onset Kufs disease versus late-infantile NCL to determine whether a genotypephenotype correlation exists. Finally, we review available data on all Kufs disease cases with a molecular diagnosis and evaluate the utility of the type A/type B classification of Kufs disease in light of molecular genetic advances.
Materials and methods

Patients
Patients were ascertained via centres with a known interest in Kufs disease and by direct referral. We collated clinical data on ancestry, sex, family history, birth and development, age of disease onset, behavioural and cognitive changes, seizure types, motor symptoms, vision, disease progression and outcome. Additionally, electrophysiological and neuroimaging data were analysed. As the cases had been ascertained over many years, the quality and completeness of the data varied.
This study was approved by the Ethics Committee at the Austin Hospital (Melbourne, Australia) and written informed consent was obtained from all patients following local IRB requirements.
Pathological review
Persistent attempts were made to source pathological material for all patients who had had previously reported biopsies (including skin, muscle, rectal, brain). All available images were subsequently reanalysed by the same expert neuropathologist (S.C.) who reported specifically on the presence or absence of curvilinear profiles, fingerprint profiles and GRODs (granular osmiophilic deposits).
Molecular genetic analysis
Genomic DNA was extracted from brain specimens using an AllPrep DNA/RNA Kit or QIAamp DNA FFPE Tissue Kit, or peripheral blood using a QIAamp DNA Maxi Kit (Qiagen).
Single nucleotide and small indel variants were identified by standard PCR on a Veriti Thermal Cycler (Applied Biosystems) and sequenced using the BigDye Õ Terminator v3.1 Cycle Sequencing protocol on an ABI 3730XL DNA Analyzer (Life Technologies Corporation). All exons, exon-intron boundaries, and untranslated regions of CLN6 (NM_017882.2) were sequenced as previously described (Arsov et al., 2011) .
Suspected deletions were investigated by single nucleotide polymorphism (SNP) genotyping, array comparative genomic hybridization (CGH), multiplex ligation-dependent probe amplification (MLPA) and droplet digital (dd)PCR analyses. SNPs in and around CLN6 were sequenced; heterozygous SNPs were deemed to be outside the deleted region. Array CGH analyses were performed with Human CGH 3x720K WholeGenome Tiling Array (Roche-NimbleGen) and Whole-Genome Cytogenetics 2.7M DNA chip (Affymetrix). MLPA probes in and around CLN6 were also designed and used for copy number estimations as described in the MRC-Holland protocol (MRC-Holland, Amsterdam, The Netherlands). Droplet digital PCR probes and primers were designed to assess gene copy number if deletions were suspected, or to interrogate specific CLN6 pathogenic variants, as we previously described (Damiano et al., 2017; Hildebrand et al., 2018) . Probe and primer sequences used in molecular genetic assays are available on request.
CLN6 phenotype-genotype correlation
We extracted a list of pathogenic CLN6 variants from the NCL mutation database (http://www.ucl.ac.uk/ncl/mutation. shtml) including those reported in Kousi et al. (2012) . The list was further curated following a review of the scientific literature in PubMed on 2 July 2018 using search term 'CLN6'. Pathogenic variants were then divided into two groups: those causing late-infantile NCL (onset 48 years) (Kousi et al., 2012; Canafoglia et al., 2015) versus teenage or adult-onset Kufs disease (onset 511 years and no visual failure) (Berkovic et al., 1988) . Kufs disease cases were further divided into those with teenage versus adult onset, where we defined teenage as 419 years. Variants were excluded when limited clinical data precluded such clinical classification or when pathogenicity was uncertain. One typical teenage-onset Kufs case could not be analysed as molecular data were not published (Lv et al., 2018) . Additionally, homozygous CLN6 missense variants were extracted from control database Genome Aggregation Database (gnomAD, version r2.0.2) (http://gnomad.broadinstitute.org/).
All pathogenic variants were classified and grouped into those predicted to result in protein truncation (e.g. nonsense, frameshift indels, canonical AE splice site, single or multi-exon deletion) versus those not (e.g. missense, non-frameshift indels). This enabled us to compare the number of unrelated patients reported to carry two truncation variants (as either homozygous or compound heterozygous pathogenic variants) versus one or zero truncation variants between the two disease groups. Multiple late-infantile NCL families with the same homozygous pathogenic variant due to a known founder effect (Kousi et al., 2012) were considered distantly related and therefore only counted once (e.g. p.Glu72* in Costa Rica, p.Ile154del in Portugal, p.Val91Glufs*42 in Newfoundland and p.Arg106Profs*26 in Pakistan).
Further, the position for each variant was plotted along the length of the CLN6 gene. Each variant was colour-coded as per its clinical classification (i.e. late-infantile NCL, teenage/ adult Kufs or control).
Data availability
Data supporting the genotype-phenotype correlation findings of this study are openly available in the NCL mutation database at http://www.ucl.ac.uk/ncl/mutation.shtml and from the gnomAD control database (version r2.0.2) at http://gnomad. broadinstitute.org/. Source clinical and pathological data are not publicly available due to their containing information that could compromise the privacy of research participants.
Results
Patients
We studied 20 patients (seven male) with Kufs disease due to recessive pathogenic variants in CLN6. Twelve of these have been previously published in varying detail (Berkovic et al., 1988; Callagy et al., 2000; Arsov et al., 2011; Muona et al., 2015; Ozkara et al., 2017) and eight cases are unpublished. New follow-up data were available on 9/ 12 previously published cases who were alive at last publication. One case published earlier (Ku8) (Arsov et al., 2011) was excluded from the clinical analysis because details were not available.
Six were sporadic cases and 14 were familial, comprising sibling pairs from seven unrelated families. Of the 13 unrelated cases and families, nine were of Italian ancestry from Italy (n = 8) and Canada (n = 1); one was a family of Maltese ancestry from Australia; and the remaining three families were from the UK, Ireland and Turkey. In two families, the parents were reported as first cousins and in another two, the parents were known to be from the same or adjacent villages in Malta and Italy, respectively.
Clinical features
The mean age of onset was 28 years (range 12-51) on a background of normal development with no significant antecedent factors reported. Onset appeared bimodal, as previously reported for Kufs overall (Berkovic et al., 1988) , with seven adolescent (onset 12-19 years) and 13 adult cases (onset 26-51 years) (Fig. 1) .
The typical presentation was of progressive myoclonus epilepsy, with myoclonic and tonic-clonic seizures, although in four patients (Cases 6b, 8a, 8b and 10) there were definitive cognitive/behavioural changes or ataxia 3-8 years before the development of seizures; in Case 5 scholastic difficulties from the age of 12 years likely represented disease onset (Table 1) .
Myoclonus was debilitating and was sometimes associated with a report of transient impaired awareness. 'Massive' myoclonus resulting in falls and myoclonic status were also reported. Generalized tonic-clonic seizures were rare in most patients and were not observed at all in three patients (Cases 4b, 6b and 11b). Repetitive tonic seizures in clusters lasting 20 min or more were described in three patients (Cases 1a, 3a and 3b).
Ataxia was the most prominent motor impairment and typically required a walking aide. Dysarthria was also prominent. Cerebellar signs in the limbs were difficult to measure due to action myoclonus. Later features included pyramidal signs and extra-pyramidal features including bradykinesia and dystonia.
EEG data were available for 18/20 cases. Epileptiform discharges that were generalized, multifocal or posteriorly predominant were observed. Data on photic stimulation were reported for all 18 cases; 17/18 were photosensitive on testing, often including at low frequency (1-5 Hz); this is consistent with what has previously been described (Berkovic et al., 1988; Guellerin et al., 2012; Canafoglia et al., 2015) . EEG background rhythms varied from normal to slow and irregular.
MRI was available for 17/20 cases. Cerebral and to a lesser extent cerebellar atrophy was evident for all. Case 9b had two normal brain MRI reports during the first 4 years following diagnosis; but mild atrophy was evident 7 years post-disease onset. Brain atrophy was reported as progressively worsening over time in multiple patients that had serial MRIs performed (Cases 1a, 6a, 9a, 9b, 10 and 11a) . No other specific brain abnormalities were consistently noted across the cohort.
Disease course
The course was slowly progressive, involving ataxia with loss of mobility and cognitive decline resulting in dementia. Two siblings had no evident cognitive decline at 20 (Case 9a) and 7 (Case 9b) years post-disease onset (Ozkara et al., 2017) . Vision loss was not observed in any patient.
Progressive ataxia and unrelenting myoclonus led to patients becoming wheelchair-bound; this occurred on average 12 years into the disease course (range 3-25; median 13). At last follow-up, six patients remained ambulant 3-20 years after disease onset (Table 1 ). Seven patients were deceased (Cases 1a, 3a, 3b, 6a, 6b, 7 and 10). Death occurred 8-31 years after onset. Thirteen cases were still alive 5-27 years after symptom onset with the oldest (Case 4b) 65 years of age (disease onset at 51). Whilst survival was often prolonged (median survival time 26 years), these patients were bed-ridden for many years.
Inter and intra-family variation
Age of onset and survival outcome varied even within the same family (Table 1) . No significant differences were evident between sexes, with mean onset age at 26 years for females (range 12-46) and 31 years for males (range 12-51) (P = 0.46, two-tailed t-test). Median survival time was 26 years for females and 22 years for males (P = 0.7, log rank test).
Pathological findings
Thirteen of 20 patients had at least one biopsy as part of their clinical work-up (Table 1) . Fingerprint profiles were the prominent diagnostic inclusions observed, although they were usually accompanied by rectilinear complex-irregular straight profiles, occasionally resolvable into pentalaminar structures (Anderson et al., 2011) . Curvilinear profiles were not seen, although they are described in the late-infantile form of CLN6 disease. Banal age-related lipofuscin was often present, and had to be distinguished from diseaserelated granular osmiophilic deposits (GRODS). Definite fingerprint profiles were found in 4/8 skin biopsies, in one neuron in 1/3 rectal biopsies, in vascular smooth muscle of 1/5 muscle biopsies and in 3/4 brain biopsies (Fig. 2) .
Molecular genetic analysis
Four unrelated patients had homozygous and nine had compound heterozygous pathogenic variants in CLN6 (Table 1 ). In two cases the genotype was inferred as DNA was unavailable (Case 3b genotype inferred from affected sister; Case 7 inferred from variants in parents). The four families with homozygous pathogenic variants were those with known or suspected consanguinity.
Most pathogenic variants were predicted to result in amino acid substitutions; however, there were four heterozygous pathogenic variants predicting protein truncation, including two small deletions and/or insertions (indels), one large deletion, and one canonical splice site change.
We previously reported that Case 5 (Ku6) was homozygous for the CLN6 pathogenic variant p.Phe238Thr (c.712_713TT4AC) (Arsov et al., 2011) . However, when the mother's DNA subsequently became available we unexpectedly discovered that she did not carry the p.Phe238Thr variant. Additional SNP, CGH, MLPA and ddPCR analyses suggested a deletion located within the 10.7 kb region chr. 15: 68 497 500-68 508 200 (GRCh37/ hg19) of CLN6. DNA sequencing across this region identified a deletion with breakpoints at nucleotides 68 498 676 and 68 504 456. The 5781 bp deletion, c.297+256_936+1802del, removes CLN6 exons 4-7 (Fig.  3) . Further analysis confirmed that this deletion was present in the affected proband and in her unaffected sister and mother.
CLN6 phenotype/genotype correlation
We compared the number of unrelated families with two, one or zero predicted truncating variants in Kufs disease (including the 13 families evaluated here plus three from the literature) (Arsov et al., 2011; Andrade et al., 2012; Kousi et al., 2012) versus 42 previously published late-infantile NCL families (Table 2 and Supplementary Table 1 ). The distribution of variants differed (P = 0.01, Fisher's exact test); 15/42 late-infantile cases had two alleles with truncation variants (predicting absence of intact CLN6 protein) whereas this was not seen in any of the 16 Kufs families.
Five of 16 Kufs families had one heterozygous variant predicting protein truncation. Cases 8a and 8b with teenageonset Kufs disease have a missense change on one allele with the other allele harbouring a heterozygous variant predicting protein truncation (splice donor variant, CLN6 c.486+1G4T); in the homozygous state, this same splice donor variant has been previously reported in a late-infantile NCL family (Teixeira et al., 2003) . Further, our literature review identified a homozygous CLN6 missense variant p.Asp256Glu that results in siblings with teenage-onset Kufs (Andrade et al., 2012) , but when coupled with truncation variant p.Tyr84* results in late-infantile NCL with onset 512 years (Faruq et al., 2014) (Supplementary Table 1) .
Heterozygous truncation variants did not appear to be preferentially seen in teenage versus adult-onset Kufs; of four cases with clear age of onset information, two began in teenage years and two had adult onset (Table 1) .
Display of the positions for pathogenic variants along the CLN6 gene did not reveal an obvious difference in variant location for the two disease groups (late-infantile NCL versus Kufs) (Fig. 4) , although no variants resulting in Kufs disease are present in exon 6. The potential for mutation hotspots along CLN6 has previously been raised (e.g. Tyr221) (Kousi et al., 2012) ; here, we can also appreciate how variants affecting the same amino acid residue can occur in either disease phenotype (i.e. Tyr84, Arg103, Arg136, Tyr142, Met241, Asp256 and Pro297) (Fig. 4 and Supplementary Table 1) . However, as highlighted earlier, it is important to consider the type of variant on the second allele. Consistent with our observation for variant p.Asp256Glu, missense changes at Arg103, Arg136 and Met241 when reported in late-infantile NCL cases were coupled with a truncation variant whereas in Kufs disease the second variant was another missense change (http:// www.ucl.ac.uk/ncl/mutation.shtml).
Although some pathogenic variants are limited to regions of the protein devoid of natural variation in the homozygous state (e.g. exons 5 and 6), this is not the case for all (Fig. 4) .
Founder mutations
Across our 13 unrelated cases, three pathogenic variants were present in multiple families. The p.Arg103Gln variant was present in Cases 1a, 1b, 10 and 13; all of Italian ancestry. The p.Met241Val variant was present in Cases 11a and 11b of Italian ancestry and Case 12 of Italian/Sicilian ancestry. Case 12 had a second variant, p.Phe238Thr, and this variant was also present in Cases 4a and 4b of Maltese and Case 5 of Sicilian origin. These observations are consistent with a founder effect for p.Arg103Gln and p.Met241Val variants in the mainland Italian population and p.Phe238Thr in both Sicily and Malta, which is geographically plausible.
Discussion
Kufs disease due to pathogenic variants in CLN6 usually presents as a progressive myoclonus epilepsy (type A Kufs) with a teenage or adult onset (onset age range 12-51 years) as previously reported (Arsov et al., 2011) . Our more extensive analysis herein highlighted that although myoclonic epilepsy is the usual presentation, a quarter of the cases had cognitive, behavioural or motor changes a few years before the first seizure. Myoclonus was documented in all, except Case 6b where data were incomplete. Frequent action myoclonus was the most debilitating clinical symptom. Photosensitivity was common, and sometimes extreme. Prominent photosensitivity is rare in adult-onset epilepsies, so it is a clinical clue to consider Kufs disease. Similarly, prolonged tonic seizures were reported in some cases, again a rare phenomenon in adult epilepsies. Tonic-clonic seizures were typically infrequent. Cognitive impairment usually emerged early and, as noted above, could be a presenting symptom but was sometimes delayed. Disease progression occurred at variable rates, even within families, with a mean time from onset to requiring a wheelchair being 12 years (median = 13) and death occurring 8-31 years after onset (median survival time = 26).
In teenage years the differential diagnosis of PME is wide, including Unverricht-Lundborg disease, Lafora disease, myoclonic epilepsy with ragged red fibres (MERRF), sialidosis, myoclonus epilepsy and ataxia due to KCNC1 mutation (MEAK), SCARB2 etc. In adult life the differential is narrower and includes MERRF, neuroserpinopathy and early-onset Alzheimer's disease (Minassian et al., 2016) .
While most cases had a progressive myoclonus epilepsy (PME) presentation, three cases did not have convulsive seizures and the clinical syndrome was that of a progressive myoclonic ataxia (PMA) (Marsden et al., 1990) . While PME and PMA are useful broad clinical syndromes to narrow down considerations for specific diagnoses, they do have some overlap (Marseille Consensus Group, 1990) . Indeed, although only two of the PMA cases had EEG studies, one had abundant generalized epileptiform discharges. A number of other disorders can have both PME and PMA presentations including MERRF (DiMauro et al., 2013) , dentatorubral-pallidoluysian atrophy (DRPLA) (Koide et al., 1994) , North Sea myoclonus (GOSR2 mutation) (Boisse Lomax et al., 2013) , action myoclonus renal failure syndrome (SCARB2 mutation) (Dibbens et al., 2009) and MEAK (Oliver et al., 2017) .
The prominent ultrastructural finding was fingerprint profiles (Fig. 2) . These are highly stereotyped and with sufficient experience easily recognized at low magnifications, even though the exact criteria for their identification demand high resolution (Carpenter et al., 1977) . The other component of the lysosomes consists of rectilinear complex. It is harder to recognize and harder to describe than the fingerprint profiles. Short pentalaminar structures are the most characteristic feature (Anderson et al., 2013) . Rectilinear complex is likely more basic to the storage process, since it probably does not occur non-specifically.
Biopsy of peripheral tissues in Kufs disease is not reliable for diagnosis. After the second decade, fingerprint profiles occur in eccrine secretory cells and vascular smooth muscle of subjects who clearly do not have any form of ceroid lipofuscinosis (Ferlazzo et al., 2012; Berkovic et al., 2016) . Reliance on findings in peripheral tissues has been an important source of misdiagnosis in Kufs disease (Berkovic et al., 1988; Pasquinelli et al., 2004) . Skin biopsy remains useful, however, for diagnosis in children. The one negative brain biopsy in this series can be ascribed to the limited number of neurons involved in Kufs disease and the necessarily limited size of brain biopsies. Importantly, genetic analysis of CLN6 in adults may obviate the need for an invasive brain biopsy in cases with a pertinent presentation.
A literature review was conducted to identify all published Kufs cases with a molecular diagnosis of either CTSF or DNAJC5 mutation and these were compared to our analysis of 20 CLN6 cases. Compatibility for each molecular diagnosis with either Kufs subtype A or B was then made, provided enough clinical data were available. Kufs type A and type B subtypes were first proposed in 1988, not to imply the presence of two separate diseases, but rather to aid clinical recognition and diagnosis (Berkovic et al., 1988) . Thirty years later, with recent molecular genetic discoveries we can see that in fact the subtypes do generally hold for different genetic aetiologies. Kufs disease due to mutation in CLN6 and DNAJC5 typically result in type A phenotype with type B predominantly accounted for by mutations in CTSF (Table 3) .
Comparison of median survival times across the three genetic aetiology groups (Table 3) suggests that DNAJC5 may have a more rapid clinical progression. However, further research with an increased sample size would be required to confirm this observation. Also, as only two recurrent DNAJC5 missense pathogenic variants have been published to date, it may be that the clinical spectrum associated with this gene is yet to be fully appreciated.
Our observation that three pathogenic CLN6 variants were present in more than one Kufs family, from similar geographical regions, is consistent with multiple founder effects. The large proportion of cases in our cohort from the Italian region is therefore not simply explained by ascertainment bias, but is also likely a product of these rare pathogenic variants being founder mutations in mainland Italy, Sicily and its neighbouring country Malta.
The question of whether the position or type of genetic variant may be a predictor of phenotype (late-infantile NCL versus Kufs) is an obvious one. Not only is the age of onset strikingly different [mean 6 years for late-infantile NCL (Mole et al., 2005) and mean 28 years for Kufs], but retinal involvement with visual failure is usual in late-infantile NCL and never observed in CLN6-related Kufs. Within Kufs cases, the bimodal age distribution also suggests there may be molecular differences between teenage and adult onset cases. Clinical support for the late-infantile NCL and Kufs distinction also comes from the observation that there are no reported families with both phenotypes; however, within Kufs families, age of onset can be variable (Table 1) , including two families (Families 1 and 9) with both teenage and adult onset. Sex did not appear to influence age of onset or survival time within the Kufs cohort.
The function of CLN6 remains enigmatic. It is a 311 amino acid transmembrane endoplasmic reticulum protein, which unlike most of the other NCL proteins, is not localized to the lysosome (Cárcel-Trullols et al., 2015) . Consistent with an earlier analysis reporting that mutation severity is associated with onset age (Kousi et al., 2012) , we found that presumed complete loss of function of CLN6 (inferred by two variants predicting protein truncation) was only observed in late-infantile NCL (Table 2) . Whilst pathogenic variants were observed within all seven exons of CLN6, no homozygous variants in the gnomAD control database were seen in exons 5 or 6 (Fig. 4) suggesting this region may be of specific functional importance. Further, the only variants present in exon 6 result in the more severe phenotype of late-infantile NCL. Interestingly, heterozygous pathogenic variants at four amino acid positions were observed with both phenotypes of lateinfantile onset and Kufs (Fig. 4) . Again, in these instances the mutation severity of the second allele was predictive of phenotypic outcome-missense variants were seen in Kufs and truncation variants in late-infantile cases. Further understanding of genotype-phenotype correlation involving missense variants will require discovery of the functional role of CLN6 and a robust functional assay.
The diagnosis of Kufs disease remains a challenge. It should be suspected in teenagers or young to middle-aged adults with PME or dementia with motor features. The age of onset is wide and the rarity of the disorder adds to the diagnostic difficulty. It is clear that there are many pitfalls to traditional pathological diagnosis. Indeed, the 'gold standard' of brain biopsy, including careful ultrastructural examination, is rarely available but now can be largely circumvented by molecular diagnosis. Pathogenic variants in CLN6 are the commonest molecular cause of Kufs disease presenting with PME in sporadic cases or siblings, but DNAJC5 variants are the likely cause in dominant pedigrees. Pathogenic variants in CTSF are the major known cause of type B Kufs; there appear to be a number of presently unsolved cases although the question of the veracity of pathological diagnosis is always an issue. For CLN6-related Kufs, the phenotype and molecular architecture are now clear. Discovery of the functional role of the protein would likely explain the mysteries of why this gene can have late-infantile and teenage-adult presentations and why the retina is spared in the latter form and perhaps provide clues to novel therapeutic strategies.
Supplementary material is available at Brain online. DNAJC5 versus CLN6 (P = 0.002) and DNAJC5 versus CTSF (P = 0.001) (Kaplan-Meier, log rank test) ( Supplementary Fig. 1 ).
